New research from Memorial Sloan Kettering Cancer Center (MSK) medical oncologist Dean Bajorin, MD, and colleagues found that patients who received nivolumab (Opdivo) after bladder cancer surgery reduced their overall risk for high-grade bladder ...
from Google Alert - health https://ift.tt/3g9wg0L
via IFTTT
0 comments:
Post a Comment